| Name | Title | Contact Details |
|---|
Tealwood Care Centers, Inc. was formed in January 1989 as a long term care, for-profit company, dedicated to serving the needs of skilled nursing facility residents. Our goals go beyond taking care of the resident's needs in a safe and comfortable
Providence Administrative Consulting Services (PACS) provides administrative support services that elevate skilled nursing facilities, empowering and equipping local leadership teams to deliver excellent care and make positive contributions to their co...
Headquartered in Memphis, Tennessee, Accredo Health Group, Inc., provides specialty pharmacy and related services for patients with certain complex and chronic conditions through our unique Therapeutic Resource Centers. Accredo is a wholly owned subsidiary of Express Scripts. Accredo’s Therapeutic Resource Centers are segmented by therapy and provide targeted therapy management programs for the following therapeutic areas: Rheumatoid arthritis Multiple sclerosis Oncology Hepatitis C Immune disorders Pulmonary arterial hypertension Hemophilia Other specialty therapies with dedicated care teams (RSV, growth deficiencies, etc.) Our services cover the range of needs posed by specialty pharmacy care. Our pharmacists and other healthcare professionals talk frequently with patients over the phone, helping them follow their treatment and educating them about their condition. And our reimbursement specialists provide b enefits research services, with an explanation to the patient or patient’s caregiver of any financial responsibility he/she may have plus prior authorization determination.
Poo~Pourri.com is the home of "Girls Dont Poop!" Shop here to buy gifts, get exclusive offers and awesome other sh*t.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.